NuVation Bio Inc.
Clinical trials sponsored by NuVation Bio Inc., explained in plain language.
A clinical-stage biopharmaceutical company developing therapies for metabolic diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Can a common heartburn pill change how a cancer drug works? Results expected Feb 2027 (estimated)
- New hope for Hard-to-Treat cancers: NUV-1511 enters human trials Results expected Mar 2027 (estimated)
-
Targeted cancer drug trial halted early: what happened?
Disease control Stopped earlyThis study tested a daily pill called AB-106 in people whose advanced solid tumors had a specific genetic change (NTRK fusion). The goal was to see if the drug could shrink tumors. The trial was stopped early after enrolling only 14 participants. It was designed for patients who …
Phase 2 • Sponsor: Nuvation Bio Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
New cancer drug trial halted early – what we know
Disease control Stopped earlyThis early-stage trial tested an experimental drug called NUV-868, alone or with other cancer drugs, in 82 adults with advanced solid tumors (including ovarian, pancreatic, prostate, and breast cancers). The goal was to find safe doses and check for early signs of effectiveness. …
Phase 1 • Sponsor: Nuvation Bio Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC